

## Media Release

Zug, 21 September 2015

### **Initial Public Offering of Nabriva Therapeutics**

Nabriva Therapeutics (NASDAQ: NBRV), a company in the portfolio of HBM Healthcare Investments, has successfully gone public. The company raised a total of USD 92 million in new capital through the issue of 9 million American Depositary Shares (ADS), at a price of USD 10.25 each. Nabriva ADS have been traded on the US Nasdaq exchange since Friday, 18 September 2015 and closed their first trading day at USD 13.24 (+29.2%).

HBM Healthcare Investments invested a total of USD 36.6 million in Nabriva prior to and including the IPO, and holds around 15% of the company. Based on the closing price on the first day of trading, the investments is valued at USD 39.3 million. Compared with the last reported book value of this stake, the Nabriva IPO increases HBM Healthcare Investments' net assets by CHF 10.4 million, or CHF 1.37 per HBM share (+1.0%).

Nabriva specialises in the development of the novel pleuromutilin class of antibiotics, which are intended to treat serious infections triggered by resistant bacteria, with a particular focus on severe skin infections and pneumonia.

Its lead product candidate, lefamulin (BC 3781) is ready to enter phase III clinical trials. The compound offers a broad spectrum of activity, oral and intravenous formulations and a positive safety profile. As the first in a novel class of antibiotics, lefamulin is thus ideally positioned for the treatment of community-acquired bacterial pneumonia (CABP).

For further information, please contact Dr. Andreas Wicki on +41 41 710 75 77, or at [andreas.wicki@hbmhealthcare.com](mailto:andreas.wicki@hbmhealthcare.com)

# NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

## HBM Healthcare Investments

### Information on HBM Healthcare Investments Ltd.

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of some 25 promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

### Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

### HBM Healthcare Investments Ltd

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 710 75 77 | Fax: +41 41 710 75 78 | [info@hbmhealthcare.com](mailto:info@hbmhealthcare.com)  
[www.hbmhealthcare.com](http://www.hbmhealthcare.com)